ello, everyone, and how are you are doing? STAT reporter Rebecca Robbins here, and I’m doing fine this morning, thanks to a steaming cup of stimulation. (No special flavor, though, I’m sorry to report.) Let’s get started on what you came here for: headlines from the world of pharma. And do send us a note if you spot anything interesting …

Novo Nordisk (NVO) scored a victory with its type 2 diabetes drug semaglutide in a late-stage trial, Reuters informs us. The drug combined with metformin successfully reduced glucose levels when tested head-to-head against a competitor from Eli Lilly (LLY).

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.